GW-597901 cinnamate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 576033

CAS#: 1144522-84-8

Description: GW-597901 cinnamate is a long-acting beta(2)-agonist.

Chemical Structure

img
GW-597901 cinnamate
CAS# 1144522-84-8
Instruction

Theoretical Analysis

MedKoo Cat#: 576033
Name: GW-597901 cinnamate
CAS#: 1144522-84-8
Chemical Formula: C34H46N2O8S
Exact Mass: 642.30
Molecular Weight: 642.810
Elemental Analysis: C, 63.53; H, 7.21; N, 4.36; O, 19.91; S, 4.99

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: GW-597901 cinnamate; GW597901 cinnamate; GW 597901 cinnamate; GW597901X; GW 597901X; GW-597901X

IUPAC/Chemical Name: 3-(4-(6-(((2R)-2-Hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl)amino)hexoxy)butyl)benzenesulfonamide; (E)-3-phenylprop-2-enoic acid

InChi Key: YAZYYGDPISTBAK-DTHFRSEHSA-N

InChi Code: InChI=1S/C25H38N2O6S.C9H8O2/c26-34(31,32)23-10-7-9-20(16-23)8-3-6-15-33-14-5-2-1-4-13-27-18-25(30)21-11-12-24(29)22(17-21)19-28;10-9(11)7-6-8-4-2-1-3-5-8/h7,9-12,16-17,25,27-30H,1-6,8,13-15,18-19H2,(H2,26,31,32);1-7H,(H,10,11)/b;7-6+/t25-;/m0./s1

SMILES Code: NS(=O)(=O)c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1.OC(=O)\C=C\c3ccccc3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO 0.0 100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 642.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. Gnadt M, Trammer B, Freiwald M, Kardziev B, Bayliss MK, Edwards CD, Schmidt M, Friedel G, Högger P. Methacholine delays pulmonary absorption of inhaled β(2)-agonists due to competition for organic cation/carnitine transporters. Pulm Pharmacol Ther. 2012 Feb;25(1):124-34. doi: 10.1016/j.pupt.2011.12.009. Epub 2012 Jan 5. PMID: 22245488.

2. Gnadt M, Trammer B, Kardziev B, Bayliss MK, Edwards CD, Schmidt M, Högger P. Comparison of the bronchodilating effects of inhaled β₂-agonists after methacholine challenge in a human lung reperfusion model. Eur J Pharm Biopharm. 2012 Aug;81(3):617-26. doi: 10.1016/j.ejpb.2012.04.013. Epub 2012 Apr 26. PMID: 22561952.